{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:11:08Z","timestamp":1792321868696,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272671"],"award-info":[{"award-number":["82272671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203219"],"award-info":[{"award-number":["82203219"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tice.2025.103185","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:00:45Z","timestamp":1760425245000},"page":"103185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["IL-8\/CXCR2 mediates resistance to apatinib through PI3K\/AKT and vasculogenic mimicry in gastric cancer cells"],"prefix":"10.1016","volume":"98","author":[{"given":"Yan-Wen","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Jing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-8771","authenticated-orcid":false,"given":"Ming-Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2025.103185_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103185_bib2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.tranon.2017.04.007","article-title":"Vascular mimicry: a novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma","volume":"10","author":"Angara","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tice.2025.103185_bib3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neo.2018.08.011","article-title":"CXCR2-expressing tumor cells drive vascular mimicry in antiangiogenic therapy\u2013resistant glioblastoma","volume":"20","author":"Angara","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.tice.2025.103185_bib4","first-page":"917","article-title":"Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies","volume":"32","author":"Angara","year":"2017","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.tice.2025.103185_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tice.2025.103185_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112791","article-title":"FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy","volume":"42","author":"Cannell","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.tice.2025.103185_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tice.2025.103185_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41420-022-01252-6","article-title":"Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tice.2025.103185_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tice.2025.103185_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-018-3584-x","article-title":"IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)","volume":"81","author":"Du","year":"2018","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.tice.2025.103185_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14656566.2015.981526","article-title":"Apatinib for the treatment of gastric cancer","volume":"16","author":"Geng","year":"2015","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.tice.2025.103185_bib12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-Cell immunotherapy in head and neck cancer models","volume":"26","author":"Greene","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tice.2025.103185_bib13","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/s41598-019-40265-7","article-title":"Morphological characteristics of vasculogenic mimicry and its correlation with EphA2 expression in gastric adenocarcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tice.2025.103185_bib14","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103185_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153903","article-title":"Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665\/miR-665\/MAPK1 axis","volume":"96","author":"Li","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.tice.2025.103185_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100987","article-title":"Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8\/PD-L1 signaling in NSCLC","volume":"70","author":"Liu","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.tice.2025.103185_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4251\/wjgo.v13.i5.366","article-title":"Molecular-targeted therapy toward precision Medicine for gastrointestinal caner: current progress and challenges","volume":"13","author":"Matsuoka","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.tice.2025.103185_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13104-018-3137-8","article-title":"Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials","volume":"11","author":"Mawalla","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.tice.2025.103185_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-019-05482-8","article-title":"Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast","volume":"179","author":"Mitra","year":"2020","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.tice.2025.103185_bib20","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1038\/s41598-017-07622-w","article-title":"Structural and functional identification of vasculogenic mimicry in vitro","volume":"7","author":"Racordon","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tice.2025.103185_bib21","first-page":"887","article-title":"Apatinib for the treatment of gastric cancer","volume":"10","author":"Roviello","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tice.2025.103185_bib22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.tice.2025.103185_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tice.2025.103185_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00109-013-1019-z","article-title":"Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme","volume":"91","author":"Soda","year":"2013","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.tice.2025.103185_bib25","first-page":"1203","article-title":"DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer","volume":"40","author":"Teng","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tice.2025.103185_bib26","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.2147\/OTT.S165899","article-title":"Prognostic significance of galectin-1 and vasculogenic mimicry in patients with gastric cancer","volume":"11","author":"You","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.tice.2025.103185_bib27","first-page":"1","article-title":"TWIST1-EP300 expedites gastric cancer cell resistance to apatinib by activating the expression of COL1A2","volume":"2022","author":"Yu","year":"2022","journal-title":"Anal. Cell Pathol."},{"key":"10.1016\/j.tice.2025.103185_bib28","first-page":"95","article-title":"MiR-129-5p restrains apatinib resistance in human gastric cancer cells via downregulating HOXC10","volume":"36","author":"Yu","year":"2021","journal-title":"Cancer Biother Radio."},{"key":"10.1016\/j.tice.2025.103185_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.tice.2025.103185_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.04.002","article-title":"Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer","volume":"454","author":"Zhai","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tice.2025.103185_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41401-022-00927-1","article-title":"Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K\/Akt signaling","volume":"44","author":"Zhao","year":"2023","journal-title":"Acta Pharm. Sin."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:10:34Z","timestamp":1785298234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816625004677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S0040816625004677"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.103185","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-8\/CXCR2 mediates resistance to apatinib through PI3K\/AKT and vasculogenic mimicry in gastric cancer cells","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.103185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103185"}}